About UChicago Medicine’s New Cancer Care & Research Pavilion

The University of Chicago Medicine is building Chicago’s first freestanding cancer care and research pavilion. The new $815 million facility combines inpatient and outpatient care along with resources to foster groundbreaking collaboration between physicians, scientists and other expert researchers from the University of Chicago. It is designed to advance cancer treatments, speed up scientific discoveries and reduce health disparities on the South Side, where cancer is the second-leading cause of death.

NUMBERS & STATISTICS

- **Size:** 575,000 square feet; seven floors, a mechanical penthouse, a lower-level support floor
- **Construction cost:** $815 million
- **Location:** East 57th Street, between South Maryland and South Drexel Avenues
- **Patient capacity:** up to 200,000 outpatient visits and 5,000 inpatient admissions per year
- **Key features:**
  - 80 private beds dedicated to patients with cancer (64 medical-surgical and 16 ICU), with family space to accommodate overnight stays
  - 90 consultation and outpatient exam rooms
  - A rapid assessment/urgent care clinic to protect immunocompromised oncology patients from exposure to infection.
  - Infusion therapy rooms grouped by cancer type to replace an outdated open design
  - Cancer imaging equipment (two MRIs, two CT scanners, two ultrasound units, two procedure rooms with mobile C-arm/fluoroscopy and an X-ray)
  - A breast center that will include screening and diagnostic imaging and biopsy rooms
  - Dedicated clinical trial spaces, for streamlined access to the latest research
  - A center focused on prevention, detection, treatment and survival, offering complementary therapies, stress reduction, community education and well-being support
  - Shell space that can expand vertically and horizontally, providing flexibility for future growth and technology.
- **Economic impact:** More than 500 construction jobs. At least 41% of contract construction dollars will go to minority-owned and woman-owned firms.
- **Architect:** CannonDesign

CANCER PAVILION TIMELINE

- January 2022 — UChicago Medicine submitted request to the state regulatory Health Facilities and Services Review Board (HFSRB) seeking a Master Design Permit to spend money on design and site planning for the proposed cancer center.
- March 2022 — HFSRB approved request for a Master Design Permit; health system began community and patient engagement efforts.
- February 2023 — UChicago Medicine filed Certificate of Need application with the HFSRB for full scope of cancer center construction.
- June 2023 — HFSRB approved plans to build new cancer pavilion, clearing the way for construction to begin.
- September 2023 — Groundbreaking, construction begins.
- 2027 — Anticipated date when new cancer hospital opens to patients.
ABOUT THE SOUTH SIDE COMMUNITY
Residents in UChicago Medicine’s service area experience a high cancer burden, largely driven by social determinants of health including access to cancer prevention, early detection and care.

- On the South Side:
  - The incidence of cancer is projected to increase 19% in the next five years, compared to 9.1% in the five collar counties surrounding the City of Chicago.
  - Cancer death rates are nearly twice the national average.
  - Cancer is the second-leading cause of death (behind heart disease) and the leading cause in five neighborhoods — Calumet Heights, East Side, Kenwood, South Deering and Woodlawn.
  - About 56% of patients leave the area to get healthcare. For cancer needs alone, 67% of residents who are seeking inpatient care leave the South Side.

- Research has found that patients living farther from healthcare facilities have worse health outcomes, longer lengths of hospital stay, lower attendance at follow-up visits, higher rates of chronic disease-related deaths and lower five-year cancer survival rates.

- To help address the access issue, a collaborative of 13 South Side providers, including UChicago Medicine, has established the South Side Healthy Community Organization, which is scoped to serve over 400,000 residents with seamless and accessible healthcare.

UCHICAGO MEDICINE’S CANCER ACHIEVEMENTS
The University of Chicago has long been recognized for its strength in basic science, translational and clinical research with fundamental and seminal contributions to understanding the basic biology of cancer and its treatment. In addition, UChicago Medicine:

- Is one of two National Cancer Institute-designated Comprehensive Cancer Centers in Illinois. The “Comprehensive” distinction is the gold standard for cancer programs bestowed by the NCI and recognizes the innovative research, leading-edge treatments, and extensive community outreach and education initiatives conducted at or by the organization.

- Is one of several dozen U.S. institutions selected as Lead Academic Participation Sites for the NCI’s National Clinical Trials Network, with more than 300 open therapeutic trials and more than 1,700 patients enrolled last year.

- Is one of 33 academic medical centers to be part of the National Comprehensive Cancer Network, a leading national alliance of cancer care organizations.

- Has been ranked for more than 17 years as one of the country’s top hospitals for cancer treatment by U.S. News & World Report.

- Has more than 200 cancer researchers and physicians working to care for patients and develop innovative new treatments. Collectively, they publish hundreds of peer-reviewed journal articles each year.

- Was the first site in the country to be certified for FDA-approved CAR T-cell therapies for specific blood cancers in both adult and pediatric patients.

- Was the first medical center in Illinois to be accredited by the Foundation for the Accreditation of Cellular Therapy for all adult and pediatric cellular therapy services.